

Piramal Enterprises Limited

April 06, 2022

Ratings

Facilities/Instruments	Amount (Rs. crore)	Rating ¹	Rating Action
Long-term Bank Facilities	1,000.00	CARE AA (CWD) (Double A) (Under Credit watch with Developing Implications)	Continues to be on Credit watch with Developing Implications
Short-term Bank Facilities	1,000.00	CARE A1+ (A One Plus)	Reaffirmed
Total Bank Facilities	2,000.00 (Rs. Two thousand crore Only)		
Market Linked Debentures	2,000.00	CARE PP-MLD AA (CWD) (Principal Protected-Market Linked Debentures Double A) (Under Credit watch with Developing Implications)	Continues to be on Credit watch with Developing Implications
Non-Convertible Debentures	3,800.00	CARE AA (CWD) (Double A) (Under Credit watch with Developing Implications)	Continues to be on Credit watch with Developing Implications
Total Long-Term Instruments	5,800.00 (Rs. Five thousand eight hundred crore only)		
Commercial Paper	6,000.00	CARE A1+ (A One Plus)	Reaffirmed
Inter Corporate Deposit	250.00	CARE A1+ (A One Plus)	Reaffirmed
Short-term Non-Convertible Debentures	450.00	CARE A1+ (A One Plus)	Reaffirmed
Total Short-term Instruments	6,700.00 (Rs. Six thousand seven hundred crore only)		

Details of instruments/facilities in Annexure-1

Detailed Rationale & Key Rating Drivers

The ratings assigned to debt instruments and bank facilities of Piramal Enterprises Limited (PEL) continues to be on 'Credit Watch with Developing Implications' as Piramal Capital & Housing Finance Limited (PCHFL; wholly owned subsidiary of PEL) was declared as the successful resolution applicant in relation to the Corporate Insolvency Resolution Process of DHFL under the Insolvency & Bankruptcy Code, 2016 and identified the resolution plan submitted by PCHFL as successful resolution plan vide the Letter of Intent (LOI) from the Administrator of DHFL.

Furthermore, as per the notification provided by PEL to the stock exchange notifications dated September 29, 2021 and October 1, 2021, PEL has informed that PCHFL has discharged the consideration to the creditors of DHFL and PCHFL has merged into DHFL with effect from 30th September 2021 under scheme of arrangement provided under the resolution plan subsequent to the approvals from Reserve Bank of India (RBI) and National Company Law Tribunal (NCLT), Mumbai. The name of the merged entity (erstwhile DHFL) was changed to 'Piramal Capital & Housing Finance Limited' w.e.f. November 2021.

Further, the company, vide its intimation to stock exchanges dated October 7, 2021, has informed that its Board of Directors has approved the Scheme of Arrangement to demerge the pharmaceuticals business and merge PHL Fininvest into PEL subject to approval from majority of the shareholders, creditors of the companies, Securities and Exchange Board of India (SEBI), stock exchanges, NCLT and other regulatory authorities as applicable.

CARE Ratings notes the DHFL merger which concluded in Q2FY22 has improved the retail proportion of AUM of Financial Services division and at the same time has also resulted in increase of gearing in line with the expectation. CARE Ratings continues to engage with the management of the PEL group to obtain a better understanding on this development on the business and financial profile and will resolve the watch once there is enough clarity on the same.

The rating continues to positively factor in the established track record of the promoter group, financial flexibility and strong position of pharma business.

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications

The rating strengths are partially constrained by PEL's moderately seasoned loan book and moderation in asset quality as well as significant exposure to the real estate sector (PEL has significant capital employed in financial services subsidiaries) in its financial services segment, concentration in the real estate loan portfolio and regulated nature of pharma division.

The group has been taking steps to reduce the proportion of wholesale book either by sell down of its exposures, refinance or other measures and has plan to reduce the level and proportion of real estate exposures in the near to medium term and bring in more granularity to the loan book by reducing the borrower concentration. CARE will continue to monitor the progress on the same.

Rating Sensitivities

Positive Factors - Factors that could lead to positive rating action/upgrade:

- Substantial reduction in exposure to real estate segment in overall loan book and single group exposure of consolidated tangible net worth on a sustained basis
- Gross NPA below 0.5% in the financial services business

Negative Factors- Factors that could lead to negative rating action/downgrade:

- Increase in the proportion of real estate loan book of PEL – Financial Services Business on a sustained basis
- Mismatch in asset liability maturities and challenges in raising long-term funding
- Deterioration in asset quality with Net NPA/ Networth (of PEL consolidated) over 10%
- Decline in PBIT margins in pharma segment below 15% on a sustained basis

Detailed description of the key rating drivers

Key Rating Strengths

Strong and resourceful promoters along with experienced management team:

PEL is the flagship company of the Piramal group headed by the Chairman, Mr Ajay Piramal. The Group is diversified with interests in Financial Services (PEL FS), Pharma (CDMO, Critical Care, OTC) and Real Estate (through a separate company). The Board is ably supported by experienced senior management team heading various verticals with adequate and relevant experience in their respective fields. PEL FS has recently planned to diversify its retail book by introducing new innovative retail products. As the group had limited experience in retail, they have onboarded industry and domain experts to further strengthen its financial services team. Furthermore, PEL FS have improved its systems and process to undertake retail book expansion.

Adequate financial flexibility supported by investments in Shriram group, equity infusion:

PEL has been raising equity capital and has been providing growth capital to its subsidiaries including pharma and financial services. During FY20 and FY21, PEL raised nearly Rs.18,173 crore of capital in the form of 10% stake sale in Shriram Transport Finance Company Ltd of Rs.2,300 crore, sale of its Healthcare and Analytics business for Rs.6,750 crore, Rights issue of Rs.3,650 crore including promoter investment of Rs.1,600 crore, Rs.1,750 crore by Preferential allotment to CDPQ and stake dilution by 20% in PPL to the Carlyle group for Rs.3,523 crore. Furthermore, to add comfort to capital requirement in PEL FS, PEL has financial flexibility in terms of its holdings in the Shriram group (20% in Shriram Capital and 10% in Shriram City Union Finance). The Shriram group is also undergoing restructuring and PEL's investments are likely to become liquid going forward. These funds were used to deleverage the balance sheet and provide capital for its financial services business. The equity generated (unallocated) through the above transactions is expected to remain in the PEL FS after demerger.

Strong position of pharma business:

During FY21, PEL transferred its Pharmaceuticals (Pharma) business to its newly formed subsidiary 'Piramal Pharma Limited' (PPL) and PPL raised ~Rs.3,500 crore from Carlyle group by diluting PEL's shareholding in PPL to 80%. Over the years, PEL has built and scaled up its pharmaceutical business through acquisitions. The pharmaceutical product portfolio of the PEL's pharma division can be categorised into global pharma and domestic consumer business. The global pharma constitutes pharma solutions (CDMO) and the critical care portfolio. In the CDMO segment, PPL is among the top three in India and the thirteenth-largest globally. PPL provides integrated solutions and offers a comprehensive range of services across the drug life-cycle – from drug discovery services and development to commercial manufacturing of drug substances and drug products. In the critical care segment, PEL is the fourth-largest producer of inhaled anaesthetics and a global player in hospital generics, and has a wide presence across the US, Europe, and more than 100 countries across the globe. In the OTC segment, PPL offers a diverse range of products, i.e., around 36 brands across categories such as skincare, vitamins and nutrition, antacids, analgesics, gastro-intestinal and baby care.

Key Rating Weaknesses

Moderate capital structure, regulated nature and intense competition for pharma division:

PEL pharma's debt profile comprises of long-term loans and fund-based working capital borrowings due to its working capital-intensive nature of its operations. The long-term loans were availed to fund large-sized acquisitions in the critical care segment. The company raised Rs.700 crore loan during 9MFY22 for acquisition of Hemmo Pharmaceuticals Limited. Despite increased debt, the gearing levels are expected to remain stable, owing to strong profitability.

Considering the nature of the product usage and application, and consequent impacts, PEL's pharma division is required to comply with various laws, rules and regulations, and operate under a strict regulatory environment. Thus, infringement in any of the laws, and any significant adverse changes in the import/export policy or environmental/regulatory policies in the area of the operations of the company, can have an impact on the company's operations. Nevertheless, it is continuously taking adequate steps to address the regulatory risks. Furthermore, all manufacturing sites continue to successfully clear regulatory

audits, conducted by various leading global regulatory agencies. The company has successfully cleared 36 USFDA inspections from FY12, including four in Q2FY21.

PEL's pharma division faces intense competition and pricing pressure in the global as well as domestic markets. Globally, the generic players are facing severe price erosions, significant government pressures to reduce prices along with intense increasing competition, increasing regulation, and increased sensitivity towards product performance.

Concentration risk and asset quality of PEL FS:

The acquisition of DHFL has helped reduce the wholesale proportion from 88% of loan book as on June 30, 2021 to 64% as on December 31, 2021, although the same continues to be still high. Real estate constitutes majority (more than 85%) of the wholesale loan book exposing itself to sector risk. While the management is trying to reduce the wholesale exposure especially real estate and client concentrations on an absolute basis and growing its retail book from the past few years, the progress has been slow. Majority of retail portfolio comprises of housing loans acquired from DHFL and a small portion of its own book. PEL FS division has started to diversify its retail book by recently launching new products like unsecured loans, SME credit, used vehicle financing, personal loans, etc and have made partnerships with fintech firms to get business.

The Gross NPA ratio of PEL FS increased from 2.5% of AUM as on March 31, 2020 to 4.1% as on March 31, 2021 on account of increase in slippages in the non-real estate wholesale portfolio. PEL reported Gross NPA of 3.3% of overall AUM as on December 31, 2021, on account of addition of DHFL assets from September 30, 2021 onwards. PEL FS does not recognize NPA on the DHFL acquired book as the same has been taken over and recognized at fair value which is significantly lower than the gross value thereby having buffer for NPA already built in the valuation. PEL FS continues to keep sufficient provisions at 4% of AUM as on December 31, 2021 to insulate itself from any further asset quality shocks. A significant proportion of wholesale book is still under moratorium. While PEL FS has adequate provisioning, asset quality will remain key monitorable going forward.

Refinancing risk for PEL FS:

The weighted average maturity profile of borrowings at PEL FS level is 3.7 years as on September 30, 2021, including borrowing for retail housing loans which is lower than the wholesale advances which typically have 3-5 years as its repayment period. Furthermore, around 46% of the debt outstanding as on December 31, 2021 of PEL FS is maturing by FY24 indicating refinance risk partly mitigated by the liquidity that PEL holds as on December 31, 2021 which is around 22% of the total debt of PEL FS and scheduled collections from the loan portfolio. PEL FS has in the past demonstrated its ability to refinance the debt. The ability of PEL FS to raise long-term funds at competitive rates is a key rating sensitivity.

Liquidity: Adequate

PEL on a consolidated level had cash and cash equivalents of around Rs.11,700 crore as on December 31, 2021 (March 31, 2021: Rs.9,180 crore) as against repayments due of Rs.16,334 crore over FY23. PEL also has access to capital market and raise funds through CP. Furthermore, it also has minority stake in the Shriram group companies which acts as an additional buffer.

Analytical approach:

CARE Ratings has assessed credit risk profile of PEL by considering the consolidated financial statements owing to financial and operational linkages between the parent and subsidiaries.

Applicable Criteria

[Policy on default recognition](#)

[Consolidation](#)

[Financial Ratios – Non financial Sector](#)

[Liquidity Analysis of Non-financial sector entities](#)

[Rating Outlook and Credit Watch](#)

[Short Term Instruments](#)

[Rating Methodology- Non-Banking Finance Companies](#)

[Pharmaceutical](#)

About the Company

Piramal Enterprises Limited (PEL) is part of the Ajay Piramal group of companies with presence in pharmaceuticals and financial services business.

Piramal pharma, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes: Pharma Solutions, an integrated contract development and manufacturing (CDMO) business; Critical Care, a complex hospital generics business and the Consumer Healthcare business, selling over-the-counter products in India.

The financial services business (PEL FS) in real estate provides housing finance and other financing solutions across the entire capital stack ranging from early stage private equity, structured debt, senior secured debt, construction finance and flexi lease rental discounting. The wholesale segment (other than real estate) has Corporate Finance Group (CFG) providing customized funding solutions to companies across sectors such as infrastructure, renewable energy, roads, industrials, auto components etc. while and Emerging Corporate Lending (ECL) focuses on lending towards Small and Medium Enterprises (SMEs). PEL FS has planned to diversify its retail book by including innovative tech driven unsecured loans, SME credit, used vehicle financing, personal loans, etc. PEL FS also has several tie-ups with leading international partners like Bain Capital (for stressed asset), APG (mezzanine investment in Infra), Ivanhoe Cambridge (Residential real estate platform), CDPQ (Senior Debt in non-Real Estate,

non-Infra sectors), CPPIB (InvIT platform of Renewables), etc. PEL FS had loan book of Rs.60,640 crore (AUM: Rs.65,792 crore) as on December 31, 2021 (March 31, 2021: Loan book – Rs.44,668 crore and AUM Rs.48,891 crore).

Brief Financials (Rs. crore)	31-03-2020 (A)	31-03-2021 (A)	9MFY22 (UA)
Total operating income	13,068	12,809	9,830
PBILDT	6,759	7,828	5,756
PAT	21	1,413	1,848
Overall gearing (times)	1.38	1.19	1.68
Interest coverage (times)	1.36	1.86	1.78

A: Audited; UA: Unaudited

Status of non-cooperation with previous CRA:

Not Applicable

Any other information:

Not Applicable

Rating history for last three years: Please refer Annexure-2

Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated for this company: Annexure 4

Annexure-1: Details of Instruments / Facilities

Name of the Instrument	ISIN	Date of Issuance	Coup on Rate	Maturity Date	Size of the Issue (Rs. crore)	Rating assigned along with Rating Outlook
Fund-based - LT-Term Loan		Proposed	-	-	1,000.00	CARE AA (CWD)
Fund-based - ST-Working Capital Limits		-	-	-	1,000.00	CARE A1+
Non-Convertible Debentures	INE140A07179	14-Jul-16	-	14-Jul-26	35.00	CARE AA (CWD)
Non-Convertible Debentures	INE140A07211	19-Jul-16	-	17-Jul-26	5.00	CARE AA (CWD)
Non-Convertible Debentures	INE140A07591	21-May-20	-	19-May-23	500.00	CARE AA (CWD)
Non-Convertible Debentures	INE140A07609	25-Jun-20	-	26-Jun-23	2,590.00	CARE AA (CWD)
Non-Convertible Debentures	INE140A07617	07-Jul-20	-	07-Jul-23	76.00	CARE AA (CWD)
Non-Convertible Debentures	INE140A07179	Proposed	-		594.00	CARE AA (CWD)
Market Linked Debentures	INE140A07633	28-Jun-21	-	28-Jun-23	365.00	CARE PP-MLD AA (CWD)
Market Linked Debentures	INE140A07633	05-Jul-21	-	28-Jun-23	125.00	CARE PP-MLD AA (CWD)
Market Linked Debentures	INE140A07641	12-Jul-21	-	12-Jan-23	102.00	CARE PP-MLD AA (CWD)
Market Linked Debentures	INE140A07658	27-Sep-21	-	27-Mar-24	400.00	CARE PP-MLD AA (CWD)
Market Linked Debentures	INE140A07666	2-Mar-22	-	2-Sep-24	125.00	CARE PP-MLD AA (CWD)
Market Linked Debentures	INE140A07666	28-Mar-22	-	2-Sep-24	175.96	CARE PP-MLD AA (CWD)
Market Linked Debentures	-	Proposed	-	-	707.04	CARE PP-MLD AA (CWD)
Commercial Paper	-	7-365 days	-	-	6,000.00	CARE A1+
Inter Corporate Deposit	-	Upto 365 days	-	-	250.00	CARE A1+
Short-Term Non-Convertible Debentures	-	Upto 365 days	-	-	450.00	CARE A1+

Annexure-2: Rating history of last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating history			
		Type	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2021-2022	Date(s) & Rating(s) assigned in 2020-2021	Date(s) & Rating(s) assigned in 2019-2020	Date(s) & Rating(s) assigned in 2018-2019
1	Debentures-Non Convertible Debentures	-	-	-				
2	Debentures-Non Convertible Debentures	LT	100.00	CARE AA (CWD)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20)	1)CARE AA; Stable (30-Dec-19) 2)CARE AA; Stable (06-May-19)	1)CARE AA; Stable (14-Sep-18)
3	Commercial Paper-Commercial Paper (Standalone)	ST	5000.00	CARE A1+	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20) 4)CARE A1+ (28-Apr-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)	1)CARE A1+ (14-Sep-18)
4	Fund-based - LT-Term Loan	LT	1000.00	CARE AA (CWD)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20)	1)CARE AA; Stable (30-Dec-19) 2)CARE AA; Stable (06-May-19)	1)CARE AA; Stable (14-Sep-18)
5	Inter Corporate Deposit	ST	250.00	CARE A1+	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)	1)CARE A1+ (14-Sep-18)
6	Commercial Paper-Commercial Paper (Standalone)	ST	1000.00	CARE A1+	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20) 4)CARE A1+ (28-Apr-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)	1)CARE A1+ (14-Sep-18)
7	Non-fund-based - ST-BG/LC	ST	-	-	-	1)Withdrawn (30-Dec-20)	1)CARE A1+ (30-Dec-19)	1)CARE A1+ (14-Sep-18)

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating history			
		Type	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2021-2022	Date(s) & Rating(s) assigned in 2020-2021	Date(s) & Rating(s) assigned in 2019-2020	Date(s) & Rating(s) assigned in 2018-2019
							2)CARE A1+ (06-May-19)	
8	Fund-based - ST-Working Capital Limits	ST	1000.00	CARE A1+	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)	1)CARE A1+ (14-Sep-18)
9	Debentures-Non Convertible Debentures	ST	450.00	CARE A1+	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20)	1)CARE A1+ (30-Dec-19)	1)CARE A1+ (07-Mar-19)
10	Debentures-Non Convertible Debentures	LT	450.00	CARE AA (CWD)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20)	1)CARE AA; Stable (30-Dec-19)	-
11	Debentures-Non Convertible Debentures	LT	250.00	CARE AA (CWD)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20)	1)CARE AA; Stable (30-Mar-20)	-
12	Debentures-Non Convertible Debentures	LT	3000.00	CARE AA (CWD)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20) 4)CARE AA; Stable (24-Apr-20)	-	-
13	Debentures-Market Linked Debentures	LT	1000.00	CARE PP-MLD	1)CARE PP-MLD AA	-	-	-

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating history			
		Type	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2021-2022	Date(s) & Rating(s) assigned in 2020-2021	Date(s) & Rating(s) assigned in 2019-2020	Date(s) & Rating(s) assigned in 2018-2019
				AA (CWD)	(CWD) (11-Oct-21) 2)CARE PP-MLD AA (CWD) (17-Jun-21)			
14	Debentures-Market Linked Debentures	LT	1000.00	CARE PP-MLD AA (CWD)	1)CARE PP-MLD AA (CWD) (11-Oct-21)	-	-	-

* Long Term / Short Term

Annexure-3: Detailed explanation of covenants of the rated instrument – Not Available

Name of the Instrument	Detailed explanation
A. Financial covenants	
I	
II	
Iii ...and so on..	
B. Non financial covenants	
I	
II	
Iii ...and so on..	

Annexure 4: Complexity level of various instruments rated for this company

Sr. No	Name of instrument	Complexity level
1	Commercial Paper (Standalone)	Simple
2	Inter Corporate Deposit	Simple
3	Short-Term Non-Convertible Debentures	Simple
4	Fund-based - LT-Term Loan	Simple
5	Fund-based - ST-Working Capital Limits	Simple
6	Non-Convertible Debentures	Simple
7.	Market Linked Debentures	Highly Complex

Annexure 5: Bank Lender Details for this Company

To view the lender wise details of bank facilities please [click here](#)

Annexure 6: Entities considered for consolidation as on March 31, 2021

Sr. no.	Subsidiary	Extent of Consolidation (%)	Rationale for consolidation
1	PHL Fininvest Private Limited	100	Wholly owned Subsidiary
2	Piramal International	100	Wholly owned Subsidiary
3	Piramal Holdings (Suisse) SA	100	Wholly owned Subsidiary
4	Piramal Critical Care Italia,SPA	80	Subsidiary
5	Piramal Critical Care Deutschland GmbH	80	Subsidiary
6	Piramal Critical Care Limited	80	Subsidiary
7	Piramal Healthcare (Canada) Limited	80	Subsidiary
8	Piramal Critical Care B.V.	80	Subsidiary
9	Piramal Pharma Solutions (Dutch) B.V.	80	Subsidiary
10	Piramal Critical Care Pty.Ltd.	80	Subsidiary
11	Piramal Healthcare UK Limited	80	Subsidiary
12	Piramal Healthcare Pension Trustees Limited	80	Subsidiary
13	Piramal Critical Care South Africa (Pty) Ltd.	80	Subsidiary
14	Piramal Dutch Holdings N.V.	80	Subsidiary
15	Piramal Healthcare Inc.	80	Subsidiary
16	Piramal Critical Care, Inc	80	Subsidiary
17	Piramal Pharma Inc.	80	Subsidiary
18	Piramal Pharma Solutions Inc.	80	Subsidiary
19	PEL Pharma Inc.	80	Subsidiary
20	Ash Stevens LLC	80	Subsidiary
21	Piramal Dutch IM Holdco B.V.	100	Wholly owned Subsidiary
22	PEL-DRG Dutch Holdco B.V.	100	Wholly owned Subsidiary
23	Piramal Capital and Housing Finance Limited	100	Wholly owned Subsidiary
24	Piramal Fund Management Private Limited	100	Wholly owned Subsidiary
25	Piramal Asset Management Private Limited	100	Wholly owned Subsidiary
26	Piramal Investment Advisory Services Private Limited	100	Wholly owned Subsidiary
27	Piramal Investment Opportunities Fund	100	Wholly owned Subsidiary
28	INDIAREIT Investment Management Co.	100	Wholly owned Subsidiary
29	Piramal Asset Management Private Limited	100	Wholly owned Subsidiary
30	Piramal Capital International Limited	100	Wholly owned Subsidiary
31	Piramal Securities Limited	100	Wholly owned Subsidiary
32	Piramal Systems & Technologies Private Limited	100	Wholly owned Subsidiary
33	Piramal Technologies SA	100	Wholly owned Subsidiary
34	PEL Finhold Private Limited	100	Wholly owned Subsidiary
35	Piramal Consumer Products Private Limited	100	Wholly owned Subsidiary
36	Piramal Pharma Limited	80	Subsidiary
37	PEL Healthcare LLC	80	Subsidiary
38	Piramal Finance Sales & Services Private Limited	100	Wholly owned Subsidiary
39	Virdis Power Investment Managers Private Limited	100	Wholly owned Subsidiary
40	Virdis Infrastructure Investment Managers Private Limited	100	Wholly owned Subsidiary
41	Convergence Chemicals Private Limited	80	Subsidiary

Note on complexity levels of the rated instrument: CARE Ratings Ltd. has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

Contact us

Media Contact

Name: Mradul Mishra
Contact no.: +91-22-6754 3573
Email ID: mradul.mishra@careedge.in

Analyst Contact

Name: Aditya R Acharekar
Contact no.: 9819013971
Email ID: aditya.acharekar@careedge.in

Relationship Contact

Name: Saikat Roy
Contact no.: +91-98209 98779
Email ID: saikat.roy@careedge.in

About CARE Ratings Limited:

Established in 1993, CARE Ratings Ltd. is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India (SEBI), it has also been acknowledged as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). With an equitable position in the Indian capital market, CARE Ratings Limited provides a wide array of credit rating services that help corporates to raise capital and enable investors to make informed decisions backed by knowledge and assessment provided by the company.

With an established track record of rating companies over almost three decades, we follow a robust and transparent rating process that leverages our domain and analytical expertise backed by the methodologies congruent with the international best practices. CARE Ratings Limited has had a pivotal role to play in developing bank debt and capital market instruments including CPs, corporate bonds and debentures, and structured credit.

Disclaimer

The ratings issued by CARE Ratings Limited are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings Limited has based its ratings/outlooks based on information obtained from reliable and credible sources. CARE Ratings Limited does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings Limited have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings Limited or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE Ratings Limited is, inter-alia, based on the capital deployed by the partners/proprietor and the current financial strength of the firm. The rating/outlook may undergo a change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE Ratings Limited is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE Ratings Limited's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

****For detailed Rationale Report and subscription information, please contact us at www.careedge.in**